IceCure Medical (NASDAQ: ICCM) notes U.S. patent allowance in 6-K

Rhea-AI Filing Summary

IceCure Medical Ltd. filed a Form 6-K to furnish a press release announcing that it was granted a notice of allowance for a U.S. patent covering its next generation XSense™ cryoprobes. The press release, dated September 18, 2025, is attached as Exhibit 99.1.

The filing also states that the first and third paragraphs of the press release, along with its “Forward Looking Statements” section, are incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8 in the United States, making this information part of those registration documents from the date of this submission.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: September 2025 (Report No. 4)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F             ☐ Form 40-F

CONTENTS

On September 18, 2025, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure Granted Notice of Allowance for U.S. Patent for its Next Generation XSense™ Cryoprobes,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K. 

The first and third paragraphs and the section titled “Forward Looking Statements” in the press release attached herewith as Exhibit 99.1 is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660, 333-267272 and 333-290046) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release dated September 18, 2025 titled “IceCure Granted Notice of Allowance for U.S. Patent for its Next Generation XSense™ Cryoprobes”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ICECURE MEDICAL LTD.
Date: September 18, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

3

FAQ

What does IceCure Medical (ICCM) report in this Form 6-K?

IceCure Medical reports that it has issued a press release titled “IceCure Granted Notice of Allowance for U.S. Patent for its Next Generation XSense™ Cryoprobes,” and furnishes that release as Exhibit 99.1.

What is the key development mentioned by IceCure Medical (ICCM)?

The key development is that IceCure has been granted a notice of allowance for a U.S. patent related to its next generation XSense™ cryoprobes, as described in the furnished press release.

How is the press release in IceCure Medical's Form 6-K used in U.S. registration statements?

The first and third paragraphs of the press release and its “Forward Looking Statements” section are incorporated by reference into IceCure Medical’s registration statements on Form F-3 and Form S-8, making them part of those filings from the date of this Form 6-K.

Which IceCure Medical registration statements are affected by this 6-K filing?

The incorporated portions of the press release become part of IceCure Medical’s Form F-3 registration statements with Registration Nos. 333-258660, 333-267272 and 333-290046, and its Form S-8 registration statements with Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587.

When was the IceCure Medical press release about the U.S. patent notice of allowance issued?

The press release titled “IceCure Granted Notice of Allowance for U.S. Patent for its Next Generation XSense™ Cryoprobes” was issued on September 18, 2025.

Who signed IceCure Medical's Form 6-K related to the U.S. patent notice of allowance?

The Form 6-K was signed on behalf of IceCure Medical Ltd. by Eyal Shamir, the company’s Chief Executive Officer, dated September 18, 2025.